nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—NTRK1—glaucoma	0.529	1	CbGaD
Regorafenib—CYP2C19—Methazolamide—glaucoma	0.0176	0.112	CbGbCtD
Regorafenib—CYP2C9—Diclofenamide—glaucoma	0.017	0.109	CbGbCtD
Regorafenib—CYP2C9—Dorzolamide—glaucoma	0.0164	0.105	CbGbCtD
Regorafenib—CYP2C19—Timolol—glaucoma	0.0149	0.0957	CbGbCtD
Regorafenib—CYP2C9—Methazolamide—glaucoma	0.0146	0.0935	CbGbCtD
Regorafenib—CYP3A4—Pilocarpine—glaucoma	0.0126	0.0805	CbGbCtD
Regorafenib—ABCB1—Timolol—glaucoma	0.0121	0.0772	CbGbCtD
Regorafenib—ABCB1—Clonidine—glaucoma	0.0102	0.0656	CbGbCtD
Regorafenib—CYP3A4—Brinzolamide—glaucoma	0.00987	0.0632	CbGbCtD
Regorafenib—CYP3A4—Dorzolamide—glaucoma	0.00953	0.061	CbGbCtD
Regorafenib—FGFR2—cornea—glaucoma	0.00878	0.191	CbGeAlD
Regorafenib—CYP3A4—Methazolamide—glaucoma	0.00849	0.0544	CbGbCtD
Regorafenib—CYP3A4—Acetazolamide—glaucoma	0.00679	0.0435	CbGbCtD
Regorafenib—CYP3A4—Clonidine—glaucoma	0.00614	0.0393	CbGbCtD
Regorafenib—FLT4—endothelium—glaucoma	0.00263	0.0571	CbGeAlD
Regorafenib—DDR2—eye—glaucoma	0.00212	0.046	CbGeAlD
Regorafenib—TEK—endothelium—glaucoma	0.00211	0.0459	CbGeAlD
Regorafenib—DDR2—retina—glaucoma	0.0021	0.0456	CbGeAlD
Regorafenib—FLT1—endothelium—glaucoma	0.00204	0.0444	CbGeAlD
Regorafenib—DDR2—connective tissue—glaucoma	0.00204	0.0443	CbGeAlD
Regorafenib—KDR—endothelium—glaucoma	0.00173	0.0375	CbGeAlD
Regorafenib—KIT—endothelium—glaucoma	0.00153	0.0332	CbGeAlD
Regorafenib—EPHX2—eye—glaucoma	0.00143	0.031	CbGeAlD
Regorafenib—EPHX2—retina—glaucoma	0.00142	0.0308	CbGeAlD
Regorafenib—FLT4—eye—glaucoma	0.00129	0.028	CbGeAlD
Regorafenib—RET—connective tissue—glaucoma	0.0011	0.0238	CbGeAlD
Regorafenib—FGFR2—eye—glaucoma	0.00108	0.0235	CbGeAlD
Regorafenib—FGFR2—connective tissue—glaucoma	0.00104	0.0226	CbGeAlD
Regorafenib—FLT1—eye—glaucoma	0.001	0.0218	CbGeAlD
Regorafenib—TEK—connective tissue—glaucoma	0.000999	0.0217	CbGeAlD
Regorafenib—RAF1—eye—glaucoma	0.000997	0.0216	CbGeAlD
Regorafenib—FLT1—retina—glaucoma	0.000994	0.0216	CbGeAlD
Regorafenib—FLT1—connective tissue—glaucoma	0.000966	0.021	CbGeAlD
Regorafenib—RAF1—connective tissue—glaucoma	0.000961	0.0209	CbGeAlD
Regorafenib—PDGFRA—connective tissue—glaucoma	0.000905	0.0197	CbGeAlD
Regorafenib—KDR—eye—glaucoma	0.000848	0.0184	CbGeAlD
Regorafenib—KDR—retina—glaucoma	0.00084	0.0182	CbGeAlD
Regorafenib—KDR—connective tissue—glaucoma	0.000817	0.0177	CbGeAlD
Regorafenib—PDGFRB—eye—glaucoma	0.000734	0.0159	CbGeAlD
Regorafenib—KIT—connective tissue—glaucoma	0.000724	0.0157	CbGeAlD
Regorafenib—PDGFRB—connective tissue—glaucoma	0.000707	0.0153	CbGeAlD
Regorafenib—ABL1—eye—glaucoma	0.000654	0.0142	CbGeAlD
Regorafenib—ABL1—retina—glaucoma	0.000648	0.0141	CbGeAlD
Regorafenib—ABL1—connective tissue—glaucoma	0.00063	0.0137	CbGeAlD
Regorafenib—Angiopathy—Travoprost—glaucoma	0.000366	0.00312	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.000364	0.0031	CcSEcCtD
Regorafenib—Mediastinal disorder—Travoprost—glaucoma	0.000363	0.00309	CcSEcCtD
Regorafenib—Angiopathy—Brinzolamide—glaucoma	0.000361	0.00308	CcSEcCtD
Regorafenib—Hypertension—Bimatoprost—glaucoma	0.00036	0.00306	CcSEcCtD
Regorafenib—Asthenia—Carteolol—glaucoma	0.000359	0.00306	CcSEcCtD
Regorafenib—Mediastinal disorder—Brinzolamide—glaucoma	0.000359	0.00306	CcSEcCtD
Regorafenib—Body temperature increased—Methazolamide—glaucoma	0.000359	0.00305	CcSEcCtD
Regorafenib—Dry mouth—Apraclonidine—glaucoma	0.000358	0.00305	CcSEcCtD
Regorafenib—Alopecia—Dorzolamide—glaucoma	0.000358	0.00305	CcSEcCtD
Regorafenib—Asthenia—Diclofenamide—glaucoma	0.000353	0.00301	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.000352	0.003	CcSEcCtD
Regorafenib—Alopecia—Brinzolamide—glaucoma	0.000352	0.003	CcSEcCtD
Regorafenib—Hypokalaemia—Betaxolol—glaucoma	0.00035	0.00298	CcSEcCtD
Regorafenib—Infection—Apraclonidine—glaucoma	0.000349	0.00297	CcSEcCtD
Regorafenib—Dry mouth—Bimatoprost—glaucoma	0.000347	0.00296	CcSEcCtD
Regorafenib—Malnutrition—Brinzolamide—glaucoma	0.000347	0.00295	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Betaxolol—glaucoma	0.000346	0.00295	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Betaxolol—glaucoma	0.000346	0.00295	CcSEcCtD
Regorafenib—Leukopenia—Acetazolamide—glaucoma	0.000344	0.00293	CcSEcCtD
Regorafenib—Nervous system disorder—Apraclonidine—glaucoma	0.000344	0.00293	CcSEcCtD
Regorafenib—Rash—Metipranolol—glaucoma	0.000341	0.0029	CcSEcCtD
Regorafenib—Skin disorder—Apraclonidine—glaucoma	0.000341	0.0029	CcSEcCtD
Regorafenib—Dermatitis—Metipranolol—glaucoma	0.000341	0.0029	CcSEcCtD
Regorafenib—Asthenia—Levobunolol—glaucoma	0.00034	0.00289	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Betaxolol—glaucoma	0.000339	0.00289	CcSEcCtD
Regorafenib—Headache—Metipranolol—glaucoma	0.000339	0.00288	CcSEcCtD
Regorafenib—Alopecia—Pilocarpine—glaucoma	0.000338	0.00288	CcSEcCtD
Regorafenib—Infection—Bimatoprost—glaucoma	0.000338	0.00288	CcSEcCtD
Regorafenib—Nervous system disorder—Bimatoprost—glaucoma	0.000334	0.00284	CcSEcCtD
Regorafenib—Skin disorder—Bimatoprost—glaucoma	0.00033	0.00281	CcSEcCtD
Regorafenib—Diarrhoea—Carbachol—glaucoma	0.000329	0.0028	CcSEcCtD
Regorafenib—Asthenia—Methazolamide—glaucoma	0.000325	0.00277	CcSEcCtD
Regorafenib—Tremor—Brinzolamide—glaucoma	0.000325	0.00277	CcSEcCtD
Regorafenib—Diarrhoea—Levobunolol—glaucoma	0.000324	0.00276	CcSEcCtD
Regorafenib—Nausea—Metipranolol—glaucoma	0.000321	0.00273	CcSEcCtD
Regorafenib—Hypertension—Brimonidine—glaucoma	0.000319	0.00271	CcSEcCtD
Regorafenib—Headache—Carteolol—glaucoma	0.000314	0.00267	CcSEcCtD
Regorafenib—Vomiting—Diclofenamide—glaucoma	0.000313	0.00267	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000312	0.00266	CcSEcCtD
Regorafenib—Tremor—Pilocarpine—glaucoma	0.000312	0.00266	CcSEcCtD
Regorafenib—Rash—Diclofenamide—glaucoma	0.000311	0.00264	CcSEcCtD
Regorafenib—Diarrhoea—Methazolamide—glaucoma	0.00031	0.00264	CcSEcCtD
Regorafenib—Headache—Diclofenamide—glaucoma	0.000309	0.00263	CcSEcCtD
Regorafenib—Dry mouth—Brimonidine—glaucoma	0.000307	0.00262	CcSEcCtD
Regorafenib—Thrombocytopenia—Acetazolamide—glaucoma	0.000307	0.00262	CcSEcCtD
Regorafenib—Vomiting—Carbachol—glaucoma	0.000306	0.0026	CcSEcCtD
Regorafenib—Hypertension—Dorzolamide—glaucoma	0.000304	0.00259	CcSEcCtD
Regorafenib—Rash—Carbachol—glaucoma	0.000303	0.00258	CcSEcCtD
Regorafenib—Hypertension—Travoprost—glaucoma	0.000303	0.00258	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000303	0.00258	CcSEcCtD
Regorafenib—Dermatitis—Carbachol—glaucoma	0.000303	0.00258	CcSEcCtD
Regorafenib—Fatigue—Apraclonidine—glaucoma	0.000303	0.00258	CcSEcCtD
Regorafenib—Headache—Carbachol—glaucoma	0.000301	0.00256	CcSEcCtD
Regorafenib—Weight decreased—Betaxolol—glaucoma	0.000301	0.00256	CcSEcCtD
Regorafenib—Pain—Apraclonidine—glaucoma	0.0003	0.00256	CcSEcCtD
Regorafenib—Infection—Brimonidine—glaucoma	0.000299	0.00255	CcSEcCtD
Regorafenib—Hypertension—Brinzolamide—glaucoma	0.000299	0.00255	CcSEcCtD
Regorafenib—Leukopenia—Pilocarpine—glaucoma	0.000298	0.00254	CcSEcCtD
Regorafenib—Nausea—Carteolol—glaucoma	0.000298	0.00253	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000297	0.00253	CcSEcCtD
Regorafenib—Headache—Levobunolol—glaucoma	0.000297	0.00253	CcSEcCtD
Regorafenib—Infestation NOS—Betaxolol—glaucoma	0.000296	0.00252	CcSEcCtD
Regorafenib—Infestation—Betaxolol—glaucoma	0.000296	0.00252	CcSEcCtD
Regorafenib—Nervous system disorder—Brimonidine—glaucoma	0.000295	0.00252	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000294	0.0025	CcSEcCtD
Regorafenib—Dry mouth—Dorzolamide—glaucoma	0.000294	0.0025	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000293	0.0025	CcSEcCtD
Regorafenib—Skin disorder—Brimonidine—glaucoma	0.000293	0.00249	CcSEcCtD
Regorafenib—Nausea—Diclofenamide—glaucoma	0.000293	0.00249	CcSEcCtD
Regorafenib—Dry mouth—Travoprost—glaucoma	0.000292	0.00249	CcSEcCtD
Regorafenib—Acute coronary syndrome—Betaxolol—glaucoma	0.000292	0.00249	CcSEcCtD
Regorafenib—Pain—Bimatoprost—glaucoma	0.000291	0.00248	CcSEcCtD
Regorafenib—Myocardial infarction—Betaxolol—glaucoma	0.000291	0.00247	CcSEcCtD
Regorafenib—Stomatitis—Betaxolol—glaucoma	0.000289	0.00246	CcSEcCtD
Regorafenib—Dry mouth—Brinzolamide—glaucoma	0.000289	0.00246	CcSEcCtD
Regorafenib—Vomiting—Methazolamide—glaucoma	0.000288	0.00246	CcSEcCtD
Regorafenib—Hypertension—Pilocarpine—glaucoma	0.000288	0.00245	CcSEcCtD
Regorafenib—Gastrointestinal pain—Apraclonidine—glaucoma	0.000287	0.00244	CcSEcCtD
Regorafenib—Rash—Methazolamide—glaucoma	0.000286	0.00243	CcSEcCtD
Regorafenib—Dermatitis—Methazolamide—glaucoma	0.000286	0.00243	CcSEcCtD
Regorafenib—Nausea—Carbachol—glaucoma	0.000286	0.00243	CcSEcCtD
Regorafenib—Infection—Travoprost—glaucoma	0.000285	0.00242	CcSEcCtD
Regorafenib—Headache—Methazolamide—glaucoma	0.000284	0.00242	CcSEcCtD
Regorafenib—Cardiac disorder—Clonidine—glaucoma	0.000284	0.00241	CcSEcCtD
Regorafenib—Nausea—Levobunolol—glaucoma	0.000281	0.00239	CcSEcCtD
Regorafenib—Infection—Brinzolamide—glaucoma	0.000281	0.00239	CcSEcCtD
Regorafenib—Nervous system disorder—Travoprost—glaucoma	0.000281	0.00239	CcSEcCtD
Regorafenib—Skin disorder—Travoprost—glaucoma	0.000278	0.00237	CcSEcCtD
Regorafenib—Abdominal pain—Apraclonidine—glaucoma	0.000277	0.00236	CcSEcCtD
Regorafenib—Nervous system disorder—Brinzolamide—glaucoma	0.000277	0.00236	CcSEcCtD
Regorafenib—Angiopathy—Clonidine—glaucoma	0.000277	0.00236	CcSEcCtD
Regorafenib—Rash—Latanoprost—glaucoma	0.000277	0.00236	CcSEcCtD
Regorafenib—Dermatitis—Latanoprost—glaucoma	0.000277	0.00235	CcSEcCtD
Regorafenib—Mediastinal disorder—Clonidine—glaucoma	0.000275	0.00235	CcSEcCtD
Regorafenib—Headache—Latanoprost—glaucoma	0.000275	0.00234	CcSEcCtD
Regorafenib—Skin disorder—Brinzolamide—glaucoma	0.000275	0.00234	CcSEcCtD
Regorafenib—Decreased appetite—Acetazolamide—glaucoma	0.000273	0.00232	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000271	0.00231	CcSEcCtD
Regorafenib—Fatigue—Acetazolamide—glaucoma	0.000271	0.0023	CcSEcCtD
Regorafenib—Infection—Pilocarpine—glaucoma	0.00027	0.0023	CcSEcCtD
Regorafenib—Alopecia—Clonidine—glaucoma	0.00027	0.0023	CcSEcCtD
Regorafenib—Nausea—Methazolamide—glaucoma	0.000269	0.00229	CcSEcCtD
Regorafenib—Thrombocytopenia—Pilocarpine—glaucoma	0.000266	0.00227	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Brimonidine—glaucoma	0.00026	0.00221	CcSEcCtD
Regorafenib—Fatigue—Brimonidine—glaucoma	0.00026	0.00221	CcSEcCtD
Regorafenib—Pain—Brimonidine—glaucoma	0.000258	0.00219	CcSEcCtD
Regorafenib—Asthenia—Apraclonidine—glaucoma	0.000252	0.00214	CcSEcCtD
Regorafenib—Decreased appetite—Dorzolamide—glaucoma	0.00025	0.00213	CcSEcCtD
Regorafenib—Tremor—Clonidine—glaucoma	0.000249	0.00212	CcSEcCtD
Regorafenib—Body temperature increased—Acetazolamide—glaucoma	0.000248	0.00211	CcSEcCtD
Regorafenib—Fatigue—Dorzolamide—glaucoma	0.000248	0.00211	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Travoprost—glaucoma	0.000247	0.00211	CcSEcCtD
Regorafenib—Fatigue—Travoprost—glaucoma	0.000247	0.0021	CcSEcCtD
Regorafenib—Cardiac disorder—Betaxolol—glaucoma	0.000247	0.0021	CcSEcCtD
Regorafenib—Pain—Dorzolamide—glaucoma	0.000246	0.0021	CcSEcCtD
Regorafenib—Decreased appetite—Brinzolamide—glaucoma	0.000246	0.00209	CcSEcCtD
Regorafenib—Weight decreased—Timolol—glaucoma	0.000246	0.00209	CcSEcCtD
Regorafenib—Pain—Travoprost—glaucoma	0.000245	0.00209	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000244	0.00208	CcSEcCtD
Regorafenib—Asthenia—Bimatoprost—glaucoma	0.000244	0.00208	CcSEcCtD
Regorafenib—Fatigue—Brinzolamide—glaucoma	0.000244	0.00208	CcSEcCtD
Regorafenib—Pain—Brinzolamide—glaucoma	0.000242	0.00206	CcSEcCtD
Regorafenib—Angiopathy—Betaxolol—glaucoma	0.000241	0.00206	CcSEcCtD
Regorafenib—Diarrhoea—Apraclonidine—glaucoma	0.00024	0.00204	CcSEcCtD
Regorafenib—Mediastinal disorder—Betaxolol—glaucoma	0.00024	0.00204	CcSEcCtD
Regorafenib—Decreased appetite—Pilocarpine—glaucoma	0.000236	0.00201	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000235	0.002	CcSEcCtD
Regorafenib—Alopecia—Betaxolol—glaucoma	0.000235	0.002	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000235	0.002	CcSEcCtD
Regorafenib—Gastrointestinal pain—Travoprost—glaucoma	0.000234	0.00199	CcSEcCtD
Regorafenib—Pain—Pilocarpine—glaucoma	0.000233	0.00198	CcSEcCtD
Regorafenib—Malnutrition—Betaxolol—glaucoma	0.000232	0.00197	CcSEcCtD
Regorafenib—Abdominal pain—Dorzolamide—glaucoma	0.000227	0.00194	CcSEcCtD
Regorafenib—Body temperature increased—Dorzolamide—glaucoma	0.000227	0.00194	CcSEcCtD
Regorafenib—Abdominal pain—Travoprost—glaucoma	0.000226	0.00193	CcSEcCtD
Regorafenib—Asthenia—Acetazolamide—glaucoma	0.000225	0.00192	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000225	0.00192	CcSEcCtD
Regorafenib—Vomiting—Apraclonidine—glaucoma	0.000223	0.0019	CcSEcCtD
Regorafenib—Gastrointestinal pain—Pilocarpine—glaucoma	0.000222	0.00189	CcSEcCtD
Regorafenib—Dry mouth—Clonidine—glaucoma	0.000222	0.00189	CcSEcCtD
Regorafenib—Dermatitis—Apraclonidine—glaucoma	0.000221	0.00188	CcSEcCtD
Regorafenib—Headache—Apraclonidine—glaucoma	0.00022	0.00187	CcSEcCtD
Regorafenib—Tremor—Betaxolol—glaucoma	0.000217	0.00185	CcSEcCtD
Regorafenib—Asthenia—Brimonidine—glaucoma	0.000216	0.00184	CcSEcCtD
Regorafenib—Infection—Clonidine—glaucoma	0.000216	0.00184	CcSEcCtD
Regorafenib—Abdominal pain—Pilocarpine—glaucoma	0.000215	0.00183	CcSEcCtD
Regorafenib—Body temperature increased—Pilocarpine—glaucoma	0.000215	0.00183	CcSEcCtD
Regorafenib—Diarrhoea—Acetazolamide—glaucoma	0.000215	0.00183	CcSEcCtD
Regorafenib—Rash—Bimatoprost—glaucoma	0.000215	0.00183	CcSEcCtD
Regorafenib—Dermatitis—Bimatoprost—glaucoma	0.000214	0.00183	CcSEcCtD
Regorafenib—Anaemia—Betaxolol—glaucoma	0.000214	0.00182	CcSEcCtD
Regorafenib—Connective tissue disorder—Timolol—glaucoma	0.000214	0.00182	CcSEcCtD
Regorafenib—Headache—Bimatoprost—glaucoma	0.000213	0.00181	CcSEcCtD
Regorafenib—Nervous system disorder—Clonidine—glaucoma	0.000213	0.00181	CcSEcCtD
Regorafenib—Thrombocytopenia—Clonidine—glaucoma	0.000213	0.00181	CcSEcCtD
Regorafenib—Skin disorder—Clonidine—glaucoma	0.000211	0.0018	CcSEcCtD
Regorafenib—Nausea—Apraclonidine—glaucoma	0.000208	0.00177	CcSEcCtD
Regorafenib—Asthenia—Dorzolamide—glaucoma	0.000206	0.00176	CcSEcCtD
Regorafenib—Asthenia—Travoprost—glaucoma	0.000206	0.00175	CcSEcCtD
Regorafenib—Asthenia—Brinzolamide—glaucoma	0.000203	0.00173	CcSEcCtD
Regorafenib—Nausea—Bimatoprost—glaucoma	0.000202	0.00172	CcSEcCtD
Regorafenib—Cardiac disorder—Timolol—glaucoma	0.000202	0.00172	CcSEcCtD
Regorafenib—ABCB1—retina—glaucoma	0.000202	0.00438	CbGeAlD
Regorafenib—Vomiting—Acetazolamide—glaucoma	0.0002	0.0017	CcSEcCtD
Regorafenib—Angiopathy—Timolol—glaucoma	0.000197	0.00168	CcSEcCtD
Regorafenib—Diarrhoea—Dorzolamide—glaucoma	0.000197	0.00168	CcSEcCtD
Regorafenib—Headache—Acetazolamide—glaucoma	0.000197	0.00167	CcSEcCtD
Regorafenib—Diarrhoea—Travoprost—glaucoma	0.000196	0.00167	CcSEcCtD
Regorafenib—Mediastinal disorder—Timolol—glaucoma	0.000196	0.00167	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000196	0.00167	CcSEcCtD
Regorafenib—Asthenia—Pilocarpine—glaucoma	0.000195	0.00166	CcSEcCtD
Regorafenib—Diarrhoea—Brinzolamide—glaucoma	0.000194	0.00165	CcSEcCtD
Regorafenib—Dry mouth—Betaxolol—glaucoma	0.000193	0.00164	CcSEcCtD
Regorafenib—Alopecia—Timolol—glaucoma	0.000192	0.00164	CcSEcCtD
Regorafenib—Rash—Brimonidine—glaucoma	0.00019	0.00162	CcSEcCtD
Regorafenib—Dermatitis—Brimonidine—glaucoma	0.00019	0.00162	CcSEcCtD
Regorafenib—Malnutrition—Timolol—glaucoma	0.000189	0.00161	CcSEcCtD
Regorafenib—Headache—Brimonidine—glaucoma	0.000189	0.00161	CcSEcCtD
Regorafenib—Decreased appetite—Clonidine—glaucoma	0.000189	0.00161	CcSEcCtD
Regorafenib—Infection—Betaxolol—glaucoma	0.000188	0.0016	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Clonidine—glaucoma	0.000187	0.0016	CcSEcCtD
Regorafenib—Fatigue—Clonidine—glaucoma	0.000187	0.00159	CcSEcCtD
Regorafenib—Nausea—Acetazolamide—glaucoma	0.000186	0.00159	CcSEcCtD
Regorafenib—Diarrhoea—Pilocarpine—glaucoma	0.000186	0.00158	CcSEcCtD
Regorafenib—Pain—Clonidine—glaucoma	0.000186	0.00158	CcSEcCtD
Regorafenib—Nervous system disorder—Betaxolol—glaucoma	0.000185	0.00158	CcSEcCtD
Regorafenib—Thrombocytopenia—Betaxolol—glaucoma	0.000185	0.00158	CcSEcCtD
Regorafenib—Skin disorder—Betaxolol—glaucoma	0.000184	0.00156	CcSEcCtD
Regorafenib—Vomiting—Dorzolamide—glaucoma	0.000183	0.00156	CcSEcCtD
Regorafenib—Rash—Dorzolamide—glaucoma	0.000181	0.00154	CcSEcCtD
Regorafenib—Dermatitis—Dorzolamide—glaucoma	0.000181	0.00154	CcSEcCtD
Regorafenib—Rash—Travoprost—glaucoma	0.000181	0.00154	CcSEcCtD
Regorafenib—Dermatitis—Travoprost—glaucoma	0.00018	0.00154	CcSEcCtD
Regorafenib—Headache—Dorzolamide—glaucoma	0.00018	0.00153	CcSEcCtD
Regorafenib—Vomiting—Brinzolamide—glaucoma	0.00018	0.00153	CcSEcCtD
Regorafenib—Headache—Travoprost—glaucoma	0.000179	0.00153	CcSEcCtD
Regorafenib—Nausea—Brimonidine—glaucoma	0.000179	0.00152	CcSEcCtD
Regorafenib—Rash—Brinzolamide—glaucoma	0.000178	0.00152	CcSEcCtD
Regorafenib—Dermatitis—Brinzolamide—glaucoma	0.000178	0.00152	CcSEcCtD
Regorafenib—Gastrointestinal pain—Clonidine—glaucoma	0.000178	0.00151	CcSEcCtD
Regorafenib—Headache—Brinzolamide—glaucoma	0.000177	0.00151	CcSEcCtD
Regorafenib—Vomiting—Pilocarpine—glaucoma	0.000173	0.00147	CcSEcCtD
Regorafenib—Abdominal pain—Clonidine—glaucoma	0.000172	0.00146	CcSEcCtD
Regorafenib—Body temperature increased—Clonidine—glaucoma	0.000172	0.00146	CcSEcCtD
Regorafenib—Rash—Pilocarpine—glaucoma	0.000171	0.00146	CcSEcCtD
Regorafenib—Dermatitis—Pilocarpine—glaucoma	0.000171	0.00146	CcSEcCtD
Regorafenib—Nausea—Dorzolamide—glaucoma	0.000171	0.00146	CcSEcCtD
Regorafenib—Headache—Pilocarpine—glaucoma	0.00017	0.00145	CcSEcCtD
Regorafenib—Nausea—Travoprost—glaucoma	0.00017	0.00145	CcSEcCtD
Regorafenib—Nausea—Brinzolamide—glaucoma	0.000168	0.00143	CcSEcCtD
Regorafenib—Decreased appetite—Betaxolol—glaucoma	0.000164	0.0014	CcSEcCtD
Regorafenib—Hypertension—Timolol—glaucoma	0.000163	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000163	0.00139	CcSEcCtD
Regorafenib—Fatigue—Betaxolol—glaucoma	0.000163	0.00139	CcSEcCtD
Regorafenib—Pain—Betaxolol—glaucoma	0.000162	0.00138	CcSEcCtD
Regorafenib—Nausea—Pilocarpine—glaucoma	0.000161	0.00138	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.00016	0.00136	CcSEcCtD
Regorafenib—Dry mouth—Timolol—glaucoma	0.000158	0.00134	CcSEcCtD
Regorafenib—Asthenia—Clonidine—glaucoma	0.000156	0.00133	CcSEcCtD
Regorafenib—Infection—Timolol—glaucoma	0.000153	0.00131	CcSEcCtD
Regorafenib—Nervous system disorder—Timolol—glaucoma	0.000151	0.00129	CcSEcCtD
Regorafenib—Skin disorder—Timolol—glaucoma	0.00015	0.00128	CcSEcCtD
Regorafenib—Body temperature increased—Betaxolol—glaucoma	0.000149	0.00127	CcSEcCtD
Regorafenib—Diarrhoea—Clonidine—glaucoma	0.000149	0.00126	CcSEcCtD
Regorafenib—Vomiting—Clonidine—glaucoma	0.000138	0.00118	CcSEcCtD
Regorafenib—Rash—Clonidine—glaucoma	0.000137	0.00117	CcSEcCtD
Regorafenib—Dermatitis—Clonidine—glaucoma	0.000137	0.00116	CcSEcCtD
Regorafenib—Headache—Clonidine—glaucoma	0.000136	0.00116	CcSEcCtD
Regorafenib—Asthenia—Betaxolol—glaucoma	0.000136	0.00115	CcSEcCtD
Regorafenib—Decreased appetite—Timolol—glaucoma	0.000134	0.00114	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Timolol—glaucoma	0.000133	0.00114	CcSEcCtD
Regorafenib—Fatigue—Timolol—glaucoma	0.000133	0.00113	CcSEcCtD
Regorafenib—Pain—Timolol—glaucoma	0.000132	0.00112	CcSEcCtD
Regorafenib—Diarrhoea—Betaxolol—glaucoma	0.000129	0.0011	CcSEcCtD
Regorafenib—Nausea—Clonidine—glaucoma	0.000129	0.0011	CcSEcCtD
Regorafenib—Gastrointestinal pain—Timolol—glaucoma	0.000126	0.00108	CcSEcCtD
Regorafenib—Body temperature increased—Timolol—glaucoma	0.000122	0.00104	CcSEcCtD
Regorafenib—Abdominal pain—Timolol—glaucoma	0.000122	0.00104	CcSEcCtD
Regorafenib—Vomiting—Betaxolol—glaucoma	0.00012	0.00102	CcSEcCtD
Regorafenib—Rash—Betaxolol—glaucoma	0.000119	0.00101	CcSEcCtD
Regorafenib—Dermatitis—Betaxolol—glaucoma	0.000119	0.00101	CcSEcCtD
Regorafenib—Headache—Betaxolol—glaucoma	0.000118	0.00101	CcSEcCtD
Regorafenib—Nausea—Betaxolol—glaucoma	0.000112	0.000956	CcSEcCtD
Regorafenib—Asthenia—Timolol—glaucoma	0.000111	0.000943	CcSEcCtD
Regorafenib—Diarrhoea—Timolol—glaucoma	0.000106	0.0009	CcSEcCtD
Regorafenib—Vomiting—Timolol—glaucoma	9.82e-05	0.000836	CcSEcCtD
Regorafenib—Rash—Timolol—glaucoma	9.74e-05	0.000829	CcSEcCtD
Regorafenib—Dermatitis—Timolol—glaucoma	9.73e-05	0.000828	CcSEcCtD
Regorafenib—Headache—Timolol—glaucoma	9.67e-05	0.000824	CcSEcCtD
Regorafenib—Nausea—Timolol—glaucoma	9.17e-05	0.000781	CcSEcCtD
Regorafenib—PDGFRB—Disease—APOE—glaucoma	6.95e-06	4.59e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FN1—glaucoma	6.94e-06	4.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CDKN2B—glaucoma	6.94e-06	4.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CDKN2B—glaucoma	6.92e-06	4.57e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—TXN—glaucoma	6.91e-06	4.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—VEGFA—glaucoma	6.9e-06	4.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—BCL2L1—glaucoma	6.89e-06	4.56e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CAV1—glaucoma	6.88e-06	4.55e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ABCA1—glaucoma	6.88e-06	4.54e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CYP1B1—glaucoma	6.88e-06	4.54e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—BAD—glaucoma	6.85e-06	4.53e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—BAD—glaucoma	6.83e-06	4.51e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—C3—glaucoma	6.79e-06	4.49e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NTRK1—glaucoma	6.76e-06	4.47e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—C3—glaucoma	6.73e-06	4.45e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—NOS3—glaucoma	6.7e-06	4.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EDN1—glaucoma	6.66e-06	4.4e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MTHFR—glaucoma	6.65e-06	4.39e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MMP9—glaucoma	6.65e-06	4.39e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EDN1—glaucoma	6.64e-06	4.39e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—glaucoma	6.59e-06	4.36e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NGF—glaucoma	6.56e-06	4.34e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—GSTM1—glaucoma	6.48e-06	4.28e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—GSTM1—glaucoma	6.48e-06	4.28e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—BAD—glaucoma	6.47e-06	4.28e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NGF—glaucoma	6.44e-06	4.26e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CDKN1B—glaucoma	6.35e-06	4.2e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NGFR—glaucoma	6.34e-06	4.19e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—APOE—glaucoma	6.33e-06	4.18e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GSTT1—glaucoma	6.33e-06	4.18e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	6.3e-06	4.16e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CAV1—glaucoma	6.27e-06	4.14e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—APOE—glaucoma	6.27e-06	4.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—BAD—glaucoma	6.25e-06	4.13e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	6.24e-06	4.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—C3—glaucoma	6.24e-06	4.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN2B—glaucoma	6.23e-06	4.12e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NOS3—glaucoma	6.21e-06	4.11e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CAV1—glaucoma	6.21e-06	4.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—APOE—glaucoma	6.19e-06	4.09e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TXN—glaucoma	6.16e-06	4.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CAV1—glaucoma	6.13e-06	4.05e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—glaucoma	6.13e-06	4.05e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—C3—glaucoma	6.13e-06	4.05e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NGF—glaucoma	6.12e-06	4.04e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—NOS3—glaucoma	6.1e-06	4.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NGF—glaucoma	6.1e-06	4.03e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	6.08e-06	4.02e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—glaucoma	6.04e-06	3.99e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—glaucoma	6.03e-06	3.98e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NTRK1—glaucoma	6.03e-06	3.98e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TXN—glaucoma	6.02e-06	3.98e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EDN1—glaucoma	5.98e-06	3.95e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—glaucoma	5.97e-06	3.94e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FN1—glaucoma	5.97e-06	3.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FN1—glaucoma	5.91e-06	3.9e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—BAD—glaucoma	5.89e-06	3.89e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—BAD—glaucoma	5.84e-06	3.86e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NOS3—glaucoma	5.83e-06	3.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CDKN1B—glaucoma	5.83e-06	3.85e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—C3—glaucoma	5.81e-06	3.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—APOE—glaucoma	5.81e-06	3.84e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—CDKN1B—glaucoma	5.81e-06	3.84e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—C3—glaucoma	5.8e-06	3.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NOS3—glaucoma	5.79e-06	3.83e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NOS3—glaucoma	5.78e-06	3.82e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—BAD—glaucoma	5.77e-06	3.81e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CAV1—glaucoma	5.75e-06	3.8e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CA1—glaucoma	5.75e-06	3.8e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—CDKN1B—glaucoma	5.73e-06	3.78e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—MTHFR—glaucoma	5.73e-06	3.78e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—MTHFR—glaucoma	5.73e-06	3.78e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—APOE—glaucoma	5.7e-06	3.77e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—glaucoma	5.7e-06	3.77e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—glaucoma	5.68e-06	3.75e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CAV1—glaucoma	5.65e-06	3.73e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	5.62e-06	3.72e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TXN—glaucoma	5.62e-06	3.71e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—glaucoma	5.58e-06	3.69e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	5.57e-06	3.68e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CTSA—glaucoma	5.57e-06	3.68e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN2B—glaucoma	5.56e-06	3.67e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NOS3—glaucoma	5.51e-06	3.64e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GSTM1—glaucoma	5.5e-06	3.63e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NGF—glaucoma	5.5e-06	3.63e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FN1—glaucoma	5.48e-06	3.62e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CDKN1B—glaucoma	5.43e-06	3.59e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CDKN1B—glaucoma	5.42e-06	3.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APOE—glaucoma	5.41e-06	3.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—BAD—glaucoma	5.41e-06	3.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APOE—glaucoma	5.4e-06	3.57e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CDKN1B—glaucoma	5.38e-06	3.56e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FN1—glaucoma	5.38e-06	3.55e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CAV1—glaucoma	5.36e-06	3.54e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	5.36e-06	3.54e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTT1—glaucoma	5.36e-06	3.54e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CAV1—glaucoma	5.35e-06	3.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EDN1—glaucoma	5.33e-06	3.52e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—APOE—glaucoma	5.33e-06	3.52e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—APOE—glaucoma	5.33e-06	3.52e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—BAD—glaucoma	5.32e-06	3.51e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—glaucoma	5.3e-06	3.5e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—CDKN1B—glaucoma	5.29e-06	3.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—glaucoma	5.28e-06	3.49e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CAV1—glaucoma	5.28e-06	3.49e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CAV1—glaucoma	5.28e-06	3.49e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CA2—glaucoma	5.26e-06	3.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—C3—glaucoma	5.22e-06	3.45e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—glaucoma	5.22e-06	3.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NOS3—glaucoma	5.2e-06	3.44e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	5.13e-06	3.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FN1—glaucoma	5.1e-06	3.37e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FN1—glaucoma	5.09e-06	3.36e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	5.08e-06	3.36e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CDKN1B—glaucoma	5.05e-06	3.34e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—BAD—glaucoma	5.04e-06	3.33e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP1B1—glaucoma	5.04e-06	3.33e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ABCA1—glaucoma	5.04e-06	3.33e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—BAD—glaucoma	5.03e-06	3.32e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CDKN1B—glaucoma	5.02e-06	3.31e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CDKN1B—glaucoma	5e-06	3.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NGF—glaucoma	4.9e-06	3.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CDKN1B—glaucoma	4.88e-06	3.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APOE—glaucoma	4.86e-06	3.21e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—MTHFR—glaucoma	4.86e-06	3.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CAV1—glaucoma	4.82e-06	3.18e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTT1—glaucoma	4.78e-06	3.16e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CDKN1B—glaucoma	4.77e-06	3.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—glaucoma	4.76e-06	3.14e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CDKN1B—glaucoma	4.76e-06	3.14e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NOS3—glaucoma	4.74e-06	3.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NOS3—glaucoma	4.69e-06	3.1e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP9—glaucoma	4.68e-06	3.09e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTT1—glaucoma	4.67e-06	3.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—C3—glaucoma	4.66e-06	3.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOS3—glaucoma	4.64e-06	3.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FN1—glaucoma	4.59e-06	3.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—BAD—glaucoma	4.53e-06	3e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—glaucoma	4.52e-06	2.99e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—glaucoma	4.51e-06	2.98e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CDKN1B—glaucoma	4.51e-06	2.98e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CAV1—glaucoma	4.48e-06	2.96e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—glaucoma	4.42e-06	2.92e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTT1—glaucoma	4.36e-06	2.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CDKN1B—glaucoma	4.35e-06	2.88e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOS3—glaucoma	4.35e-06	2.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—glaucoma	4.34e-06	2.86e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	4.32e-06	2.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CAV1—glaucoma	4.3e-06	2.84e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOS3—glaucoma	4.27e-06	2.82e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ABCA1—glaucoma	4.27e-06	2.82e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP1B1—glaucoma	4.27e-06	2.82e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—glaucoma	4.24e-06	2.8e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—glaucoma	4.2e-06	2.78e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CDKN1B—glaucoma	4.11e-06	2.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FN1—glaucoma	4.09e-06	2.7e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CDKN1B—glaucoma	4.07e-06	2.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOS3—glaucoma	4.06e-06	2.68e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOS3—glaucoma	4.04e-06	2.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—BAD—glaucoma	4.04e-06	2.67e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GSTM1—glaucoma	4.03e-06	2.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CDKN1B—glaucoma	4.02e-06	2.65e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—NOS3—glaucoma	3.99e-06	2.64e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—NOS3—glaucoma	3.99e-06	2.64e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—glaucoma	3.97e-06	2.62e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.85e-06	2.55e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCA1—glaucoma	3.81e-06	2.52e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1B1—glaucoma	3.81e-06	2.52e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—glaucoma	3.8e-06	2.51e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CDKN1B—glaucoma	3.77e-06	2.49e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—glaucoma	3.77e-06	2.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ABCA1—glaucoma	3.72e-06	2.46e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1B1—glaucoma	3.72e-06	2.46e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TXN—glaucoma	3.71e-06	2.45e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CDKN1B—glaucoma	3.7e-06	2.45e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—glaucoma	3.65e-06	2.41e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—glaucoma	3.65e-06	2.41e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOS3—glaucoma	3.64e-06	2.41e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MTHFR—glaucoma	3.56e-06	2.35e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.51e-06	2.32e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CDKN1B—glaucoma	3.51e-06	2.32e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CDKN1B—glaucoma	3.5e-06	2.32e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—glaucoma	3.49e-06	2.31e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1B1—glaucoma	3.47e-06	2.29e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCA1—glaucoma	3.47e-06	2.29e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—glaucoma	3.43e-06	2.27e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—glaucoma	3.41e-06	2.26e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTM1—glaucoma	3.41e-06	2.25e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—NOS3—glaucoma	3.39e-06	2.24e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—glaucoma	3.38e-06	2.23e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—glaucoma	3.32e-06	2.19e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CAV1—glaucoma	3.28e-06	2.17e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—glaucoma	3.25e-06	2.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—glaucoma	3.25e-06	2.15e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—glaucoma	3.25e-06	2.14e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—glaucoma	3.17e-06	2.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1B—glaucoma	3.16e-06	2.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—glaucoma	3.13e-06	2.07e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—glaucoma	3.1e-06	2.05e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—glaucoma	3.08e-06	2.03e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTM1—glaucoma	3.04e-06	2.01e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—glaucoma	3.01e-06	1.99e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—glaucoma	3e-06	1.98e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—glaucoma	2.97e-06	1.96e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—glaucoma	2.92e-06	1.93e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—glaucoma	2.92e-06	1.93e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—glaucoma	2.91e-06	1.93e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—glaucoma	2.87e-06	1.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—glaucoma	2.81e-06	1.86e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—glaucoma	2.81e-06	1.85e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAV1—glaucoma	2.78e-06	1.84e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—glaucoma	2.78e-06	1.83e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—glaucoma	2.69e-06	1.78e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—glaucoma	2.63e-06	1.74e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—glaucoma	2.63e-06	1.73e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—glaucoma	2.61e-06	1.72e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—glaucoma	2.58e-06	1.7e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—glaucoma	2.56e-06	1.69e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—glaucoma	2.51e-06	1.66e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—glaucoma	2.48e-06	1.64e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAV1—glaucoma	2.48e-06	1.64e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—glaucoma	2.45e-06	1.62e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—glaucoma	2.45e-06	1.62e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAV1—glaucoma	2.42e-06	1.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—glaucoma	2.37e-06	1.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—glaucoma	2.34e-06	1.55e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—glaucoma	2.33e-06	1.54e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCA1—glaucoma	2.29e-06	1.51e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1B1—glaucoma	2.29e-06	1.51e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—glaucoma	2.28e-06	1.51e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—glaucoma	2.27e-06	1.5e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAV1—glaucoma	2.26e-06	1.5e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—glaucoma	2.21e-06	1.46e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—glaucoma	2.2e-06	1.45e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—glaucoma	2.1e-06	1.39e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—glaucoma	1.98e-06	1.31e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—glaucoma	1.92e-06	1.27e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—glaucoma	1.88e-06	1.24e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—glaucoma	1.83e-06	1.21e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—glaucoma	1.83e-06	1.21e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—glaucoma	1.77e-06	1.17e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—glaucoma	1.72e-06	1.13e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—glaucoma	1.71e-06	1.13e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—glaucoma	1.68e-06	1.11e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—glaucoma	1.62e-06	1.07e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—glaucoma	1.57e-06	1.03e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—glaucoma	1.51e-06	9.95e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAV1—glaucoma	1.49e-06	9.86e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—glaucoma	1.13e-06	7.46e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—glaucoma	1.03e-06	6.82e-06	CbGpPWpGaD
